BNP Paribas Financial Markets
EBAC

BNP Paribas Financial Markets’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

BNP Paribas Financial Markets’s Portfolio EBAC Stock Details EBAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-496,000
Closed -$3.69M – 4901
2022
Q3 		$3.69M Buy
+496,000
New +$4.89M 0.01% 1527

Other funds holding EBAC

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

BNP Paribas Financial Markets's EBAC Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q4 2022, closing a stake of 496,000 shares — an estimated $3.69M sold.

BNP Paribas Financial Markets first reported a position in EBAC in Q3 2022 and held it in 1 quarter. The position peaked at $3.69M in Q3 2022. 50 funds tracked by Wall St. Rank hold EBAC as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 496,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q4 2022, an estimated $3.69M.
  • BNP Paribas Financial Markets first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2022 and held it in 1 quarter.
  • BNP Paribas Financial Markets's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $3.69M in Q3 2022.
  • 50 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.